KALA BIO, Inc. (KALA) Stock Analysis & Investment Frameworks
KALA BIO, Inc. (KALA) stock analysis on Invetso. Review KALA BIO, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
KALA BIO, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
KALA BIO, Inc. Key Financial Metrics
- Market Cap: $3.59M
- Revenue: $N/A
- ROE: -222.32%
- ROIC: -232.05%
- Dividend Yield: N/A
About KALA BIO, Inc.
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
KALA BIO, Inc. Investment Frameworks
Invetso analyzes KALA BIO, Inc. (KALA) across the following frameworks:
- KALA BIO, Inc. 10Y Growth Potential
- KALA BIO, Inc. Scenario Analysis
- KALA BIO, Inc. Risks & Opportunities
- KALA BIO, Inc. Economic Moat
- KALA BIO, Inc. Business Model
- KALA BIO, Inc. Management
- KALA BIO, Inc. SWOT Analysis
- KALA BIO, Inc. Porter's 5 Forces
- KALA BIO, Inc. PESTLE Analysis
- KALA BIO, Inc. ESG Analysis